Kontafarma China
Kontafarma China, officially known as Kontafarma Limited, is a prominent player in the pharmaceutical and healthcare industry, headquartered in Hong Kong. Founded in 2005, the company has established a strong presence across Asia, focusing on the development and distribution of innovative healthcare solutions. Specialising in prescription medications, over-the-counter products, and health supplements, Kontafarma is recognised for its commitment to quality and efficacy. The company’s unique approach combines advanced research with a deep understanding of local market needs, allowing it to deliver tailored solutions that enhance patient care. With a reputation for excellence, Kontafarma has achieved significant milestones, including strategic partnerships and a growing portfolio of proprietary products. As a trusted name in the industry, Kontafarma continues to strengthen its market position, contributing to the advancement of healthcare in the region.
DitchCarbon Score
How does Kontafarma China's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Real Estate Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kontafarma China's score of 17 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kontafarma China's reported carbon emissions
In 2024, Kontafarma China reported Scope 2 emissions of approximately 1,470,000 kg CO2e. This marks an increase from 2023, where Scope 2 emissions were about 1,057,000 kg CO2e. The company has not disclosed any Scope 1 or Scope 3 emissions data for these years. Kontafarma China is committed to reducing its carbon footprint, with specific targets set for both Scope 1 and Scope 2 emissions. The company aims to achieve these reductions between 2023 and 2025, as part of its broader commitment to sustainable development and the low-carbon transition. The exact percentage of reduction has not been specified. The emissions data for Kontafarma China is cascaded from its parent company, Kontafarma China Holdings Limited, reflecting the corporate family relationship. This data is crucial for understanding the company's overall environmental impact and its efforts towards climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 1,487,000 | 0,000,000 | - | - |
| Scope 2 | 3,922,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kontafarma China is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
